This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-03. Anything still debated is marked as such rather than presented as settled.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
== History == 1977 The Association was founded. 1982 The first international conference was held in Rome. 1992 the first member's directory was produced. The first glossy member's newsletter was printed in 1993 and in 1998 it became Quasar. 1998 also saw the launch of the first BARQA website. 2001 The Association launched a new membership structure: Affiliate, Associate, Member, Fellow and Honorary Member grades. 2005 Saw the first Global QA Conference held with Society of Quality Assurance (SQA) and Japan Society of Quality Assurance (JSQA) in Orlando, Florida. 2012 India Regional Forum launched. 2013 The 1st European QA Conference with DGGF and SoFAQ was held in Bonn, Germany. 2015 US Regional Forum established. 2017 The Association celebrated its 40th birthday and 5th RQA/SQA/JSQA Global Conference held in Edinburgh.
Ribosomally synthesized and post-translationally modified peptides (RiPPs), also known as ribosomal natural products, are a diverse class of natural products of ribosomal origin. Consisting of more than 20 sub-classes, RiPPs are found in all three domains of life, and they possess a wide range of biological functions. As a consequence of the falling cost of genome sequencing, scientific interest in RiPPs has increased in the last few decades. Because RiPPs are more closely predictable from raw genomic data than other natural products (e.g. alkaloids and terpenoids), their presence in sequenced organisms can, in theory, be identified rapidly. This makes RiPPs an attractive target of modern natural product discovery efforts.
Collagen alpha-1(XXV) chain is a protein that in humans is encoded by the COL25A1 gene. COL25A1 is a brain-specific membrane-bound collagen. Proteolytic processing releases CLAC, a soluble form of COL25A1 containing the extracellular collagen domains that associates with senile plaques in Alzheimer disease (AD; MIM 104300) brains (Osada et al., 2005).[supplied by OMIM]
Sources: en.wikipedia.org
In a joint statement on 13 January 2026, the prime ministers of Greenland and Denmark said that Greenland was facing an "unacceptable pressure" campaign and a "geopolitical crisis" caused by the US. They said that Greenland is not for sale under any circumstances. Frederiksen said, "our message is clear: Greenland is not for sale" and "you can't buy another people". Nielsen emphasised that talk about buying another people shows a lack of respect, and that Greenland does not want to be owned nor governed by the US. Greenlandic politicians have welcomed a NATO mission in Greenland to protect the island following Trump's threats.
It was definitively accepted by the Fédération Cynologique Internationale in 1954. In the fifteen years from 2007 to 2021, the annual number of new registrations in Germany averaged about 485, with a low of 390 and a high of 607.
This changeover to ESPN was originally to begin with WrestleMania 42 in April 2026, but in August 2025, it was announced the deal had been moved up. NXT's PLEs continued to air on Peacock until March 15, 2026, with Peacock only maintaining the Saturday Night's Main Event (SNME) specials as well as replays of recent episodes of SmackDown until at least 2029 as well as exclusive documentaries; outside the US, SNME streams on YouTube. In January 2026, more countries merged under Netflix, while Sub-Saharan Africa and Japan remained on SuperSport and Abema, respectively. On April 1, 2026, the last four remaining countries that were still on the standalone WWE Network transitioned to Netflix, permanently shutting down the WWE Network after 12 years. After Peacock lost NXT's PLEs in March, one event streamed on YouTube in April before WWE began a new deal with The CW in June in which 20 NXT PLEs would air on The CW's linear channel, and then beginning in August, NXT's events also began simulcasting on ESPN's streaming service. On October 1, Japan merged under Netflix. In addition to ESPN, WWE's events are still made available on traditional PPV outlets in the United States. WWE also partnered with Fandango to broadcast PLEs in select theaters across the United States, beginning with the 2025 SummerSlam, which was initially exclusive to select Regal Cinemas, with events after SummerSlam expanding to other theater chains. In Canada, WWE's PLEs are available through Vu!, Shaw PPV, or SaskTel PPV, and was formerly shown in select locations of the Cineplex Entertainment chain.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.